INM - InMed's INM-901 Shows Significant Reduction in Neuroinflammation in Long-Term Preclinical AD Study

2025-01-21 08:57:35 ET

DENVER, Colo., Jan 21, 2025 ( 247marketnews.com )- InMed Pharmaceuticals (NASDAQ: INM ) reported promising results from a long-term preclinical Alzheimer’s Disease (AD) study. INM-901 demonstrated a reduction in several markers of neuroinflammation, a known factor in Alzheimer’s development and progression.

Results from the study, which used a well-established Alzheimer’s disease model, revealed several key findings.

INM-901 treatment led to a dose-dependent and statistically significant reduction in plasma pro-inflammatory cytokines, including TNF-?, IL-1ß, and INF-?. Deregulated cytokine networks are linked to tissue inflammation and neurodegeneration in Alzheimer’s disease.

The high-dose INM-901 group showed a dose-dependent and statistically significant decrease in neurofilament light chain (NfL) in plasma. NfL is a biomarker released by neurons in response to injury, used to assess neurodegeneration in diseases like Alzheimer’s.

mRNA assessments confirmed a reduction in several key neuroinflammatory genes in the brain, such as GFAP, CD-33, and TLR-2, further supporting the study’s findings.

Dr. Eric Hsu, InMed’s Senior Vice President of Preclinical R&D ted, “We are highly encouraged by the data from our long-term preclinical Alzheimer’s study. The results suggest that INM-901 may reduce neuroinflammation, which is a key factor in Alzheimer’s disease. This finding is especially exciting as neuroinflammation has become a new target for drug development, alongside traditional approaches that focus on amyloid beta plaques and tau protein tangles.

“Alzheimer’s disease is a complex condition with multiple contributing factors, and INM-901 may help address these various pathologies, making it a promising candidate for treatment.”

InMed is currently analyzing additional data from the study to better understand the mechanisms of action of INM-901 and its potential role in treating Alzheimer’s. These analyses will focus on assessing CB1/CB2 and PPAR receptor activity. They will also evaluate markers for neuronal differentiation and function, as well as investigate cellular stress responses and survival.

InMed expects to complete these analyses in the coming weeks.

To learn more about INM-901 and its potential in Alzheimer’s treatment, visit InMed Pharmaceuticals .

The Role of Neuroinflammation in Alzheimer’s Disease

Recent research has identified neuroinflammation as a crucial factor in the onset and progression of Alzheimer’s. Inflammation and subsequent neurodegeneration in the brain establish a link between neuroinflammation and Alzheimer’s disease.

Pro-inflammatory cytokines such as TNF-?, IL-1ß, and INF-? promote inflammation and are implicated in the pathogenesis of Alzheimer’s. Research suggests these cytokines are released during the disease’s progression. By reducing pro-inflammatory cytokines, treatments could slow or even halt the inflammatory process, preventing further neurodegeneration and disease progression.

While inflammation may have a protective role early in the disease, prolonged immune activation can worsen neuronal damage. As a result, targeting neuroinflammation is becoming a promising therapeutic strategy for Alzheimer’s, with ongoing efforts to develop drugs that modulate microglial activity, reduce cytokine levels, and promote a protective immune response.

(Source: Alzheimer’s Association, “Inflammation as a Central Mechanism in Alzheimer’s Disease”)

The post InMed’s INM-901 Shows Significant Reduction in Neuroinflammation in Long-Term Preclinical AD Study appeared first on 24/7 MarketNews .

For further details see: